Annual Report 2021

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2021 85 The United Laboratories International Holdings Limited Annual Report 2021 5. REVENUE AND SEGMENT INFORMATION (Continued) Segment information HKFRS 8 Operating Segments requires operating segments to be identified on the basis of internal reports about components of the Group that are regularly reviewed by the chief operating decision maker (“CODM”) (i.e. executive directors of the Company) for the purpose of allocating resources to segments and assessing their performance. The three revenue streams are the operating and reportable segments of the Group on which the Group reports its primary segment information. (a) Segment revenue and results Year ended 31 December 2021 Intermediate Bulk Finished Segment products medicine products total Elimination Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 REVENUE External sales 1,700,337 3,968,575 4,034,526 9,703,438 – 9,703,438 Inter-segment sales 1,684,837 585,413 – 2,270,250 (2,270,250) – Segment revenue 3,385,174 4,553,988 4,034,526 11,973,688 (2,270,250) 9,703,438 RESULT Segment profit 396,151 202,220 875,571 1,473,942 Unallocated other income 147,311 Unallocated corporate expenses (106,227) Unallocated other gains and losses, net 41,799 Impairment losses under expected credit loss model, net of reversal (293,947) Finance costs (60,231) Profit before taxation 1,202,647